I'm sure you saw the press release today. I suggest that you don't get
caught up in the message board conspiracy theorists, as you can see, the
person who made assumptions that our data must be "Terrible" ended up
apologizing on the board for misinforming everyone.
Currently, the standard of care for late stage melanoma patients is
Yervoy/Zelboraf (this has changed, as it used to be chemotherapy). With
the improved response rates seen so far with Anti PD-1 (and without the
toxicity that comes with Yervoy/Zelboraf), it has been predicted by many
in the scientific field that Anti-PD-1 will become the new standard of
care (it was just designated by the FDA as 'breakthrough status' - meaning
the FDA will do an accelerated review of it.
The thing is, you're seeing an average response rate of about 35% of
Anti-PD 1, which means there's still about 65% who are non-responders.
OncoSec added a research study to see if ImmunoPulse can turn non
responding cells to responding cells. The data so far has been
So while we are moving forward with the development of ImmunoPulse, we
also feel we are at the right time, right place with our current strategy
to explore ImmunoPulse as a combination approach. The melanoma landscape
is quickly changing, and we have the right people on board and are
positioning ourselves to be competitive in this space.
I noticed that the timeline has changed and excludes potential dates for
trial results. It has been mentioned that there is a bait and switch
going on. The person believes results are "TERRIBLE" because Oncosec is
turning their attention to solid tumors instead of skin cancer. I own
25,000 shares and I need a little transparency. Why did the timeline
change? Why the focus on PD-1 when we are waiting for results for
melanoma, merkel cell, etc. Are results that bad?
It's actually more common than you may believe. I know for a fact that representatives of other companies that I own shares in do monitor these message boards. I have spoken to them and that has come up in the conversation. That being said, I'm not sure Amy Chan appreciates her email being made public. Maybe she doesn't mind. I for one appreciate her openness with the shareholders.